

Export of Pharmaceutical products

from Hubei Province

In order to assess how the shutdown of Hubei province from COVID-19 will affect the export of pharmaceutical products to the international market , export data from China Customs has been obtained and analysed.

I. Identification of key pharmaceutical categories of commodities

In the China Customs statistics database about China exports, data of the following commodities have been selected for analysis:

HS3001, defined as: Glands and other organs for organotherapeutic use, dried, whether or not powdered, extracts of glands or other organs or of their secretions for organotherapeutic uses, heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses , not elsewhere specified or included.

HS3002, defined as:

Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic use; antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products

HS3003, defined as: Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sales.

II. What pharmaceutical products were exported from Hubei

All exported commodities HS3001, HS3002, and HS3003 from Hubei in 2019 are shown the Annex 1 charts 'Hubei Export Data 2019'.

III. Will the Hubei shutdown affect the pharmaceutical product exports?

In combating the COVID-19, the Wuhan municipal government announced the closure of the city on 23rd January 2020. All roads to and from the city were closed (the train still stops and allows arrival at Wuhan, but no departures). Other cities in the province followed the move of the capital city immediately. As from 27th January, the whole

province with a total of 59.17 million inhabitants has been closed down. When life and work gradually will resume in other regions of China (after a long spring festival 'holiday' period), it is at the moment impossible to predict when the tight control on Hubei can be released.

If the production and export in Hubei cannot resume to the previous level short term, this will have an impact on the below indicated categories of pharmaceutical products. But the impact will most likely be limited, as the Hubei pharmaceutical export only accounts for small proportion in the overall export of China.

The chart below shows the commodity category which accounted for more than 2% in any given year during the past 3 years.

HS Code	Commodity	2019	2018	2017
30019010	Heparin & its salts	2.9%	0.18%	4.6%
30029030	Bacteria and virus		38.75%	5.5%
30029090	Human & animal blood for medical use; microbial cultures; toxins		5%	3.9%
30021400	Mixed immunological products, neither in measured doses nor in retail packings		0.1%	19.3%

III. Conclusion

Hubei province is not a major export region for raw pharmaceutical products (HS3001,3002&3003) in China. Therefore, the tight control of Hubei for the COVID-19 is not likely to impact the international market very much, for the above-mentioned product categories, if other regions of the country steadily resume normal level of production and export.

Annex 1: Hubei Export Data 2019

HS Code	Commodity	Export Quantity Hubei (kg)	Export Value Hubei (USD)	USD Proportion Hubei / whole China	Export from whole China (kg)	Export from whole China (USD)
30012000	Extracts of glands or other organs or of their secretions	0	124,840	1%	68,513	12,720,422
30019010	Heparin & its salts	5,479	31,857,754	2.9%	201,038	1,106,074,605
30019090	Substances of human or animal origin, for therapeutic use	3,680	682,685	0.4%	2,943,482	153,353,688
30032090	Medicaments of antibiotics, neither in measured doses nor in retail packing	0	3,495		26,0472,671	260,472,671
30039000	Medicaments consisting of two or more constituents, neither in measured doses nor in retail packing	61,179	267,138	0.07%	23,299,688	346,230,315

Annex 2: Definition of HS3001, 3002 & 3003 in also ChineseHS3001

Glands and other organs for organotherapeutic uses, dried, whether or not powdered, extracts of glands or other organs or of their secretions for organotherapeutic uses, heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included.

已干燥的器官疗法用腺体及其他器官，不论是否制成粉末；器官疗法用腺体、其他器官及其分泌物的提取物；肝素及其盐；其他供治疗或预防疾病用的其他品目未列名的人体或动物制品

HS3002

Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic use; antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxines, cultures of micro-organisms (excluding yeasts) and similar products

人血，治病、防病或诊断用动物血制品；抗血清、其他血份及免疫制品，不论是否修饰通过生物工艺加工制得；疫苗、毒素、培养微生物（不包括酵母）及类似产品

HS3003

Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sales.

两种或两种以上成分混合而成的治病或防病药品（不包括品目3002，3005或3006的货品），未配定剂量或制成零售包装